
Empagliflozin Tablets
Form: Tablets
Strength: 10 mg, 25 mg
Reference Brands: Jardiance(EU & US)
Category: Diabetes
Empagliflozin is a selective SGLT2 inhibitor approved for managing type 2 diabetes mellitus, heart failure, and chronic kidney disease. In the USA, the FDA approved Jardiance (10 mg, 25 mg) in 2014. In the EU, it is authorized by the EMA under centralized procedure. It is often prescribed as monotherapy or in combination with metformin or insulin. Empagliflozin improves glycemic control and reduces cardiovascular risks. Regular renal monitoring is advised. Pharmatradz.com connects global buyers and suppliers with licensed manufacturers of Empagliflozin, ensuring regulatory-compliant sourcing for B2B needs in both regulated and semi-regulated markets.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Related Products
Premixed Insulins (70/30, 50/50) Injectable
Strength: U-100
Form: Vials, pens
Reference Brands: Humulin, Novolin(US); Mixtard, Humulin, Insuman(EU)
View Details Get EnquiryInsulin Lispro (Humalog) injectable
Strength: U-100, U-200
Form: Vials/pens
Reference Brands: Humalog, Admelog, Fiasp(US); Humalog, Fiasp(EU)
View Details Get EnquiryInsulin Aspart (Novolog) injectable
Strength: U-100, U-200
Form: Vials/pens
Reference Brands: Novolog, Fiasp(US &EU)
View Details Get EnquiryInsulin Glargine (Lantus) injectable
Strength: U-100, U-300
Form: Vials/pens
Reference Brands: Lantus, Basaglar, Toujeo(US); Lantus, Toujeo(EU)
View Details Get Enquiry